Drug Interactions between ACAM2000 and upadacitinib
This report displays the potential drug interactions for the following 2 drugs:
- ACAM2000 (smallpox and mpox vaccine)
- upadacitinib
Interactions between your drugs
upadacitinib smallpox and monkeypox vaccine
Applies to: upadacitinib and ACAM2000 (smallpox and mpox vaccine)
MONITOR: Administration of the smallpox and monkeypox vaccine, which contains a live, attenuated, non-replicating strain of orthopoxvirus, to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.
MANAGEMENT: It is generally advisable to complete recommended vaccinations, including smallpox and monkeypox vaccine, before starting immunosuppressant or antineoplastic treatment. Clinicians should consult public health authorities and thoroughly assess risks versus benefits prior to administering the smallpox and monkeypox vaccine to immunosuppressed individuals. If the decision is made to vaccinate, titer testing by the Centers for Disease Control and Prevention (CDC) might be considered on a case-by-case basis. Because a correlate of protection has not been established and there is no known antibody titer level that will ensure protection, titer results should be interpreted with caution to avoid providing a false sense of security. Additionally, since immunosuppressed patients might be less likely to mount an effective vaccine response, infections may occur even after full vaccination and outcomes could be particularly severe in these patients, especially following exposure to more virulent orthopoxviruses. Therefore, vaccine recipients might consider avoiding high-risk exposures until after completion of immunosuppressive therapies. Regardless of vaccination status, all individuals who work with orthopoxviruses should wear appropriate personal protective equipment.
References (4)
- CDC Centers for Disease Control and Prevention (2019) General Best Practice Guidelines for Immunization: Altered Immunocompetence. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf
- (2021) "Product Information. Jynneos (smallpox and monkeypox vaccine)." Bavarian Nordic, Inc.
- Rao AK, Petersen BW, Whitehill F, et al. (2022) "Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices--United States, 2022 ht"
- Anonymous. (2022) Updated ATAGI Clinical Guidance on Vaccination Against MPX (Monkeypox) https://www.health.gov.au/sites/default/files/documents/2022/08/atagi-clinical-guidance-on-vaccination-against-monkeypox.pdf
Drug and food interactions
upadacitinib food
Applies to: upadacitinib
GENERALLY AVOID: Grapefruit, grapefruit juice or supplements containing grapefruit may increase the plasma concentrations of upadacitinib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in these fruits. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with grapefruit. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Upadacitinib side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.
MONITOR CLOSELY: Smoking during treatment with upadacitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies. During upadacitinib clinical studies, current or past smokers had an additional increased risk of overall malignancies. Also, upadacitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.
MANAGEMENT: The manufacturer advises that concomitant use of upadacitinib with grapefruit, grapefruit juice, or supplements containing grapefruit should be avoided. Caution is advised if upadacitinib is prescribed to current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing upadacitinib in patients who have experienced a myocardial infarction or stroke.
References (2)
- (2022) "Product Information. Rinvoq (upadacitinib)." AbbVie Pty Ltd, 7
- (2022) "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.